{"protocolSection": {"identificationModule": {"nctId": "NCT02561130", "orgStudyIdInfo": {"id": "REMIT-Dapa"}, "organization": {"fullName": "Population Health Research Institute", "class": "OTHER"}, "briefTitle": "Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga", "officialTitle": "Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga"}, "statusModule": {"statusVerifiedDate": "2020-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-12-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-09-16", "studyFirstSubmitQcDate": "2015-09-24", "studyFirstPostDateStruct": {"date": "2015-09-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-08-17", "resultsFirstSubmitQcDate": "2020-11-02", "resultsFirstPostDateStruct": {"date": "2020-11-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-11-02", "lastUpdatePostDateStruct": {"date": "2020-11-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Population Health Research Institute", "class": "OTHER"}, "collaborators": [{"name": "AstraZeneca", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising Forxiga, metformin, basal insulin glargine and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.", "detailedDescription": "This is a multicentre, open-label, randomized controlled trial in 152 patients with recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 12-week course of treatment with Forxiga, metformin, insulin glargine and lifestyle therapy, and (b) standard diabetes therapy, and followed for a total of 64 weeks (1 year and 3 months). In all participants with HbA1C\\<7.3% at the 12 week visit, glucose-lowering medications will be discontinued and participants will be encouraged to continue with lifestyle modifications and regular glucose monitoring. Participants with HbA1C \u2265 7.3% at this visit or who experience hyperglycemia relapse after stopping drugs will receive standard glycemic management as informed by the current Canadian Diabetes Association clinical practice guidelines."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Diabetes", "Insulin", "Glargine", "Metformin", "Forxiga", "Diet", "Exercise", "Lifestyle"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 154, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Intervention", "type": "EXPERIMENTAL", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise", "interventionNames": ["Drug: insulin glargine", "Drug: metformin", "Drug: Forxiga", "Behavioral: Lifestyle therapy"]}, {"label": "Standard Care", "type": "NO_INTERVENTION", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "interventions": [{"type": "DRUG", "name": "insulin glargine", "description": "Dose is titrated to achieve fasting normoglycemia", "armGroupLabels": ["Intervention"], "otherNames": ["Lantus"]}, {"type": "DRUG", "name": "metformin", "description": "Dose is titrated to 1 g bid or maximal tolerated dose", "armGroupLabels": ["Intervention"]}, {"type": "DRUG", "name": "Forxiga", "description": "Dose is titrated to 10 mg po daily or maximal tolerated dose", "armGroupLabels": ["Intervention"], "otherNames": ["dapagliflozin"]}, {"type": "BEHAVIORAL", "name": "Lifestyle therapy", "description": "Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving", "armGroupLabels": ["Intervention"], "otherNames": ["diet and exercise"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group", "description": "Drug-free diabetes remission is defined as HbA1C \\< 6.5 % off glucose-lowering agents for at least 12 weeks.", "timeFrame": "24 weeks after randomization"}], "secondaryOutcomes": [{"measure": "Number of Participants Achieving Drug-free Diabetes Remission", "description": "Drug-free diabetes remission is defined as HbA1C \\< 6.5 % off glucose-lowering agents for at least 12 weeks.", "timeFrame": "64 weeks after randomization"}, {"measure": "Number of Participants Achieving Drug-free HbA1C < 6.0%", "description": "Drug-free complete diabetes remission is defined as HbA1C \\< 6.0 % off glucose-lowering agents for at least 12 weeks.", "timeFrame": "24 weeks after randomization"}, {"measure": "Number of Participants Achieving Diabetes Relapse Without Overt Hyperglycemia Off Diabetes Drugs", "description": "Diabetes relapse without overt hyperglycemia is defined as HbA1C 6.5-6.9% off glucose-lowering agents for at least 12 weeks.", "timeFrame": "24 weeks"}, {"measure": "Glycated Hemoglobin (HbA1C)", "description": "Expressed in Diabetes Control and Complications Trial (DCCT) units", "timeFrame": "12 weeks after randomization"}, {"measure": "Number of Participants With Non-severe Symptomatic Hypoglycemic Episodes", "description": "Symptomatic hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia.", "timeFrame": "During 64 weeks of follow-up"}, {"measure": "Percentage of Weight Loss From Baseline", "description": "(Weight at randomization - weight at 12 weeks)/(weight at randomization)", "timeFrame": "12 weeks after randomization"}, {"measure": "Change in Waist Circumference From Baseline", "description": "(Waist circumference at 12 weeks - waist circumference at randomization)", "timeFrame": "12 weeks after randomization"}, {"measure": "Number of Participants With Severe Hypoglycemic Episodes", "description": "Severe hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following: (i) the event was associated with a documented self-measured or laboratory plasma glucose level \\</= 2.0 mmol/L or (ii) the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.", "timeFrame": "During 64 weeks of follow-up"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. men and women 30-80 years of age inclusive;\n2. type 2 diabetes mellitus diagnosed by a physician within 8 years prior to patient enrollment;\n3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks prior to screening and randomization;\n4. HbA1C 6.5-9.5% inclusive on no hypoglycemic agents or HbA1C \u2264 8.0% on up to 2 glucose-lowering agents;\n5. body mass index \u2265 23 kg/m2;\n6. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);\n7. ability and willingness to self-inject insulin;\n8. provision of informed consent.\n\nExclusion Criteria:\n\n1. current use of insulin therapy;\n2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance;\n3. history of end-stage renal disease or renal dysfunction as evidenced by eGFR\\<60 mL/min/1.73 m2 by MDRD formula;\n4. history of lactic acidosis or diabetic ketoacidosis;\n5. active liver disease or elevated alanine transferase (ALT) levels \u2265 2.5 times upper limit of normal at the time of enrollment;\n6. history of bladder cancer or undiagnosed hematuria;\n7. history of breast cancer;\n8. history of polycythemia;\n9. evidence of volume depletion or hypotension (systolic blood pressure \\< 90 mmHg);\n10. systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 105 mmHg;\n11. diagnosed cardiovascular disease (unless cleared for a moderate intensity exercise program by a specialist) including:\n\n    1. any history of acute coronary syndrome, hospitalization for unstable angina, myocardial infarction, or revascularization with coronary artery bypass grafting or percutaneous coronary intervention;\n    2. other evidence of coronary artery disease;\n    3. peripheral vascular disease, valvular heart disease, cardiomyopathy, aortic dissection, tachyarrhythmias, bradyarrhythmias, prior stroke or TIA;\n    4. prior hospitalization for heart failure; or\n    5. ECG findings concerning for ischemic heart disease (i.e. pathological Q-waves, ST-segment-T-wave abnormalities in contiguous leads, left anterior hemiblock, left bundle branch block, second or third degree atrioventricular block).\n12. dependence on oxygen;\n13. history of any disease requiring frequent intermittent or continuous systemic glucocorticoid treatment;\n14. history of bariatric surgery, or planned bariatric surgery in the next 1.5 years;\n15. history of any major illness with a life expectancy of \\< 3 years;\n16. history of injury or any other condition that significantly limits participant's ability to achieve moderate levels of physical activity;\n17. any history of excessive alcohol intake, acute or chronic;\n18. currently pregnant, or breastfeeding, or not using a reliable method of birth control for the duration of the trial in all females with childbearing potential; reliable methods of birth control include oral contraceptive (birth control pill), hormonal injection, implant, patch, or vaginal ring, intrauterine device, barrier method (condom and spermicide), tubal ligation, partner vasectomy or abstinence;\n19. known hypersensitivity to metformin, Forxiga, or insulin glargine.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Natalia McInnes, MD", "affiliation": "McMaster University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Hertzel C Gerstein, MD", "affiliation": "Hamilton Health Sciences Corporation", "role": "STUDY_CHAIR"}], "locations": [{"facility": "University of Calgary", "city": "Calgary", "state": "Alberta", "zip": "T2T 5C7", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Health Science Centre", "city": "Winnipeg", "state": "Manitoba", "zip": "R3E 3P4", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "McMaster University", "city": "Hamilton", "state": "Ontario", "zip": "L8N 3Z5", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "St. Joseph's Hospital", "city": "London", "state": "Ontario", "zip": "N6A 4V2", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "Western University", "city": "London", "state": "Ontario", "zip": "N6G 2M1", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "LMC", "city": "Toronto", "state": "Ontario", "zip": "M4G 3E8", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "St. Michaels's Hospital", "city": "Toronto", "state": "Ontario", "zip": "M5C 2T2", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}]}, "referencesModule": {"references": [{"pmid": "32403130", "type": "DERIVED", "citation": "McInnes N, Hall S, Sultan F, Aronson R, Hramiak I, Harris S, Sigal RJ, Woo V, Liu YY, Gerstein HC. Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin. J Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa248. doi: 10.1210/clinem/dgaa248."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "FG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "77"}, {"groupId": "FG001", "numSubjects": "77"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "76"}, {"groupId": "FG001", "numSubjects": "76"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "BG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "154"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.8", "spread": "10.0"}, {"groupId": "BG001", "value": "56.7", "spread": "9.6"}, {"groupId": "BG002", "value": "56.8", "spread": "9.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "54"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "100"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "125"}]}]}, {"title": "Non-Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "29"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "154"}]}]}]}, {"title": "Duration of diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37.7", "spread": "26.7"}, {"groupId": "BG001", "value": "35.8", "spread": "27.8"}, {"groupId": "BG002", "value": "36.8", "spread": "27.2"}]}]}]}, {"title": "Glycated hemoglobin (HbA1C)", "description": "Expressed in Diabetes Control and Complications Trial (DCCT) units", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of glycated hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.7", "spread": "0.6"}, {"groupId": "BG001", "value": "6.7", "spread": "0.7"}, {"groupId": "BG002", "value": "6.7", "spread": "0.6"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.3", "spread": "5.8"}, {"groupId": "BG001", "value": "32.5", "spread": "6.0"}, {"groupId": "BG002", "value": "32.9", "spread": "5.9"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group", "description": "Drug-free diabetes remission is defined as HbA1C \\< 6.5 % off glucose-lowering agents for at least 12 weeks.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "13"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Drug-free Diabetes Remission", "description": "Drug-free diabetes remission is defined as HbA1C \\< 6.5 % off glucose-lowering agents for at least 12 weeks.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "64 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Drug-free HbA1C < 6.0%", "description": "Drug-free complete diabetes remission is defined as HbA1C \\< 6.0 % off glucose-lowering agents for at least 12 weeks.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Diabetes Relapse Without Overt Hyperglycemia Off Diabetes Drugs", "description": "Diabetes relapse without overt hyperglycemia is defined as HbA1C 6.5-6.9% off glucose-lowering agents for at least 12 weeks.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "9"}]}]}]}, {"type": "SECONDARY", "title": "Glycated Hemoglobin (HbA1C)", "description": "Expressed in Diabetes Control and Complications Trial (DCCT) units", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycated hemoglobin", "timeFrame": "12 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.9", "spread": "0.4"}, {"groupId": "OG001", "value": "6.6", "spread": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Non-severe Symptomatic Hypoglycemic Episodes", "description": "Symptomatic hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "During 64 weeks of follow-up", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "15"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Weight Loss From Baseline", "description": "(Weight at randomization - weight at 12 weeks)/(weight at randomization)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of weight loss", "timeFrame": "12 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.9", "spread": "3.2"}, {"groupId": "OG001", "value": "1.0", "spread": "2.5"}]}]}]}, {"type": "SECONDARY", "title": "Change in Waist Circumference From Baseline", "description": "(Waist circumference at 12 weeks - waist circumference at randomization)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm", "timeFrame": "12 weeks after randomization", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.0", "spread": "4.1"}, {"groupId": "OG001", "value": "-1.3", "spread": "3.3"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Severe Hypoglycemic Episodes", "description": "Severe hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following: (i) the event was associated with a documented self-measured or laboratory plasma glucose level \\</= 2.0 mmol/L or (ii) the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "During 64 weeks of follow-up", "groups": [{"id": "OG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving"}, {"id": "OG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "64 weeks", "eventGroups": [{"id": "EG000", "title": "Intervention", "description": "Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise\n\ninsulin glargine: Dose is titrated to achieve fasting normoglycemia\n\nmetformin: Dose is titrated to 1 g bid or maximal tolerated dose\n\nForxiga: Dose is titrated to 10 mg po daily or maximal tolerated dose\n\nLifestyle therapy: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving", "deathsNumAffected": 0, "deathsNumAtRisk": 77, "seriousNumAffected": 3, "seriousNumAtRisk": 77, "otherNumAffected": 12, "otherNumAtRisk": 77}, {"id": "EG001", "title": "Standard Care", "description": "Standard glycemic care as informed by the current clinical practice guidelines", "deathsNumAffected": 0, "deathsNumAtRisk": 77, "seriousNumAffected": 0, "seriousNumAtRisk": 77, "otherNumAffected": 10, "otherNumAtRisk": 77}], "seriousEvents": [{"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Viral gastroenteritis", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Resection of liver metastases from colorectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}], "otherEvents": [{"term": "Genitourinary infection", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}]}, {"term": "Other infections", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 77}]}, {"term": "Abscess drainage", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Abdominal pain", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Moderate renal dysfunction defined as GFR 30-60 ml/min/1.73m2", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 77}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Natalia McInnes", "organization": "McMaster University", "email": "natalia.mcinnes@mcmaster.ca", "phone": "905-521-2100"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2015-07-15", "uploadDate": "2020-08-12T11:38", "filename": "Prot_SAP_000.pdf", "size": 377435}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M13570", "name": "Phenylpropanolamine", "relevance": "LOW"}, {"id": "M9238", "name": "Guaifenesin", "relevance": "LOW"}, {"id": "M186319", "name": "Chlorpheniramine, phenylpropanolamine drug combination", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnObAg", "name": "Anti-Obesity Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}